Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
I was glad to see that almost everyone realized that when a GLP-1 agonist is added to a sulfonylurea that it is not the GLP-1 agonist that is responsible for any side effects
Tirzepatide, the dual GIP/GLP-1 agonist, has shown even greater efficacy in the SURMOUNT trials, with patients losing up to 22.5% of body weight
Splitting the dose across two weeks would create unpredictable hormone fluctuations, potentially leading to inconsistent appetite suppression, metabolic dysregulation, or unnecessary side effects
GLP-1 is a glucose-dependent intestinal hypoglycemic polypeptide hormone secreted by L cells of the terminal jejunum, ileum and colon
The DMC reviewed overall safety data to determine patterns and trends of events, or to identify safety issues throughout the trial
